Phase I study of vinorelbine and paclitaxel by 3-hour simultaneous infusion with and without granulocyte colony-stimulating factor support in metastatic breast carcinoma

Cancer

Volumn 91, Issue 4, 2001, Pages 664-671

  Ibrahim, Nuhad K ^a,b   Buzdar, Aman U ^a   Valero, Vicente ^a   Dhingra, Kapil ^a   Willey, Jie ^a   Hortobagyi, Gabriel N ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Advanced breast carcinoma; Maximum tolerated dose; Paclitaxel; Toxicity; Vinorelbine

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; NAVELBINE; PACLITAXEL;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FATIGUE; FEMALE; FEVER; GRANULOCYTOPENIA; HUMAN; MAXIMUM TOLERATED DOSE; METASTASIS; MYALGIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROPHYLAXIS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; PACLITAXEL; VINBLASTINE;

EID: 0035864913     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20010215)91:4<664::AID-CNCR1049>3.0.CO;2-P     Document Type: Article

References (77)

1. Immunofluorescence study of the action of Navelbine, vincristine and vinblastine on mitotic and axonal microtubules
2. Navelbine. Portions of this supplement were presented at a symposium. Lugano, Switzerland, October 31, 1988
3. Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy
4. Phase II trial of weekly IV vinorelbine in first-line advanced breast cancer chemotherapy
5. Vinorelbine as first-line chemotherapy for metastatic breast carcinoma
6. Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer
7. Phase II trial of weekly IV vinorelbine as a single agent in first-line advanced breast cancer chemotherapy: The Latin-American experience
8. A phase II multicentre UK study of vinorelbine in advanced breast cancer
9. Monotherapy of metastatic breast cancer: A review of newer agents
10. Vinorelbine an active new drug in breast carcinoma: Results of an ARTAC phase II trial
11. Vinorelbine is an active anti-proliferative agent in pre-treated advanced breast cancer patients: A phase II study
12. Vinorelbine (Navelbine) as a salvage treatment for advanced breast cancer
13. Activity of vinorelbine in advanced breast cancer: Preliminary results of a phase II trial
14. Vinorelbine as second line treatment in anthracycline pre-treated advanced breast cancer patients: A phase II study
15. Salvage chemotherapy with vinorelbine in advanced breast cancer
16. Weekly vinorelbine in previously treated patients with advanced breast cancer: Preliminary results
17. Phase II trial of vinorelbine/doxorubicin as first-line therapy of advanced breast cancer
18. A multicenter phase II study of Navelbine and doxorubicin as first-line chemotherapy of metastatic breast cancer
19. Phase II study of sequential Navelbine and doxorubicin for the treatment of metastatic breast cancer: Preliminary results
20. Preliminary data on 4′epiadriamycin, vinorelbine: A new active combination in advanced breast cancer
21. Weekly epirubicin plus vinorelbine in advanced breast cancer: Preliminary results
22. Results of a combination of Navelbine and fluorouracil in advanced breast cancer with a group sequential design
23. A US multicenter phase II study of IV Navelbine and 5-flourouracil as first-line treatment of patients with advanced breast cancer
24. Vinorelbine, 5-fluorouracil and leucovorin in advanced breast cancer: A pilot phase II study
25. Effective second line chemotherapy of advanced breast cancer with navelbine and mitomycin C
26. Navelbine (vinorelbine) and mitomycin C: Combination therapy in advanced breast cancer
27. Vinorelbine and mitomycin-C in anthracycline-pretreated advanced breast cancer patients
28. Vinorelbine containing regimens in three different schedules for the treatment of advanced breast cancer
29. Mitomycin-C and vinorelbine as second line chemotherapy for metastatic breast cancer
30. Cisplatin-vinorelbine: A new active combination in metastatic breast cancer
31. Treatment of metastatic breast cancer with vinorelbine and cisplatin: A clinical phase II trial
32. A phase II study of carboplatin and vinorelbine as second line treatment for advanced breast cancer
33. Taxol® (paclitaxel) alone is equivalent to CMFP combination chemotherapy as frontline treatment in metastatic breast cancer
34. Single-agent paclitaxel as first-line treatment of metastatic breast cancer: The British experience
35. 3-Hr high-dose Taxol (T) infusion following standard Adriamycin-cyclophosphamide (AC) in advanced or high risk breast cancer (BC): A NSABP feasibility study
36. 3-Hr high-dose taxol (T) infusion in advanced breast cancer (ABC): An NSABP phase II study
37. Effect of Taxol duration of infusion in advanced breast cancer (ABC): Results from NSABP B-26 trial comparing 3- to 24-hour infusion of high-dose Taxol
38. Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer
39. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer
40. A multicenter, randomized study of two schedules of paclitaxel in patients with advanced breast cancer
41. Failure of higher dose paclitaxel to improve outcome in patients with metastatic breast cancer - Results from CALGB 9342
42. Efficacy and cardiac effects of 3-H paclitaxel (P) plus bolus doxorubicin (DOX) in women with untreated metastatic breast carcinoma
43. Three-year follow-up in women with metastatic breast cancer after bolus doxorubicin and paclitaxel (AT) infused over 3 hours
44. A phase I/II study: Doxorubicin and paclitaxel (sequential combination) in the treatment of advanced breast cancer
45. Doxorubicin and paclitaxel, a highly active combination in the treatment of metastatic breast cancer
46. No clinical cardiotoxicity associated with Taxol® (paclitaxel) + doxorubicin as first-line treatment for metastatic breast cancer (MBC)
47. A phase II study of doxorubicin/paclitaxel plus G-CSF for metastatic breast cancer
48. Phase III trial of doxorubicin (A) vs paclitaxel (T) vs doxorubicin + paclitaxel (A + T) as first-line therapy for metastatic breast cancer (MBC): An intergroup trial
49. Phase II trial of doxorubicin plus paclitaxel plus G-CSF in metastatic breast cancer: An Eastern Cooperative Oncology Group study (E4195)
50. Taxol-cisplatinum (T-P) in patients (PTS) with breast cancer previously treated with an anthracycline containing regimen
51. Phase I/II trial of biweekly paclitaxel and cisplatin in the treatment of metastatic breast cancer
52. Phase II trial of biweekly paclitaxel and cisplatin in advanced breast carcinoma: An Eastern Cooperative Oncology Group study
53. Paclitaxel by 3-h infusion and carboplatin in anthracycline-resistant advanced breast cancer. A phase II study conducted by the Hellenic Cooperative Oncology Group
54. Paclitaxel and carboplatin as first-line chemotherapy for advanced breast cancer
55. Phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast cancer (MBC): A North Central Cancer Treatment Group trial
56. Paclitaxel/5-fluorouracil/leucovorin in metastatic breast cancer: A Vanderbilt Cancer Center phase II trial
57. Taxol® (T) plus doxorubicin (D) in the treatment of metastatic breast cancer (MBC) in ambulatory patients (PTS)
58. Chemotherapy for metastatic breast cancer
59. Vinorelbine tartrate and paclitaxel combination: Enhanced activity against in vivo p388 murine leukemia cells
60. Bcl2 is the guardian of microtubule integrity
61. Kinetics of mitotic arrest and apoptosis in murine mammary and ovarian tumors treated with Taxol
62. Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel
63. Growth suspension of human head and neck cancer cells by the introduction of a wild-type p53 gene via a recombinant adenovirus
64. Heterogeneity in the development of apoptosis in irradiated murine tumours of different histologies
65. Antiproliferative and apoptotic effects of vinorelbine on human myeloma cells
66. P-glycoprotein mediated resistance to 5′-nor-anhydro-vinblastine (Navelbine®)
67. Digital morphonuclear analysis of sensitive versus resistant neoplastic cells to vinca-alkaloids, alkylating, and intercalating drugs
68. Schedule-dependent interactions between vinorelbine and paclitaxel in human carcinoma cell lines in vitro
69. A phase I study of sequential vinorelbine followed by paclitaxel
70. Combination paclitaxel and vinorelbine therapy: In vitro cytotoxic interactions and dose-escalation study in breast cancer patients previously exposed to anthracyclines
71. Phase I/II study of paclitaxel and vinorelbine in metastatic breast cancer
72. Paclitaxel plus vinorelbine in metastatic breast cancer patients with contraindications to receive anthracyclines
73. Vinorelbine and paclitaxel as first-line chemotherapy in metastatic breast cancer
74. First-line chemotherapy with vinorelbine and paclitaxel as simultaneous infusion in advanced breast cancer